Pharmaceutical Dosage Form For Immediate Release Of An Indolinone Derivative

Patent No. EP2313087 (titled "Pharmaceutical Dosage Form For Immediate Release Of An Indolinone Derivative") was filed by Boehringer Ingelheim on Jun 4, 2009. The application was issued on Nov 22, 2023.

Patent Summary

Pharmaceutical dosage form of the active substance 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate that delivers an immediate release profile with at least 70% dissolution in 60 minutes under specific in vitro conditions. The dosage form is a viscous lipid suspension containing the drug in medium chain triglycerides, hard fat, and lecithin. It can be in capsule or tablet form. The lipid suspension provides rapid dissolution and absorption of the drug.

Patent Family

Patent Family

Patent Oppositions (4)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP2313087

BOEHRINGER INGELHEIM
Application Number
EP09757601A
Filing Date
Jun 4, 2009
Status
Patent Maintained As Amended
Oct 20, 2023
Publication Date
Nov 22, 2023